NOT.F - Novartis AG

Frankfurt - Frankfurt Delayed Price. Currency in EUR
80.16
0.00 (0.00%)
At close: 7:57PM CEST
Stock chart is not supported by your current browser
Previous Close80.16
Open0.00
Bid80.11 x 30000
Ask80.34 x 30000
Day's Range0.00 - 0.00
52 Week Range
Volume1,589
Avg. Volume0
Market Cap179.698B
Beta (3Y Monthly)0.24
PE Ratio (TTM)16.47
EPS (TTM)4.87
Earnings DateN/A
Forward Dividend & Yield2.51 (3.13%)
Ex-Dividend Date2019-03-04
1y Target EstN/A
  • Rising tide of East Bay biotech deals promises millions of square feet
    American City Business Journals

    Rising tide of East Bay biotech deals promises millions of square feet

    Wareham Development built up the East Shore biotech real estate market. Now other players are making a splash with new projects and tenants.

  • New Gilead CFO: Let's Make a Deal
    GuruFocus.com

    New Gilead CFO: Let's Make a Deal

    The nearly $83 billion biotech giant seems poised to supercharge its M&A; and partnership efforts Continue reading...

  • Investors Beware: Tilray Stock Might Not Be Done Dropping
    InvestorPlace

    Investors Beware: Tilray Stock Might Not Be Done Dropping

    Tilray (NASDAQ:TLRY), like other cannabis equities, continues to suffer from the effects of the bursting stock bubble. Tilray stock traded as high as $300 per share during the run-up in marijuana stocks, which preceded Canadian legalization in 2018. Since then, it has lost more than 92% of its value. This includes a nearly 35% drop in less than a week following its August earnings report.Source: Shutterstock To be sure, declines have hammered marijuana stocks across the board. Also, once the dust settles, the company holds key assets and partnerships that could eventually take TLRY stock higher.However, Tilray stock needs both changing sentiment and a more discernible path to stability before it can stem its decline.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sector Selloff Hits TLRY StockTLRY trades at just over $22 per share. Despite this massive drop, TLRY stock still appears overvalued. Currently, it trades at about 24.3 times sales.In fairness, cannabis stocks have dropped across the board. Both Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) trade near 52-week lows. Moreover, companies such as Aphria (NYSE:APHA), which just beat earnings by 10 cents CAD per share, have also struggled. Many blame both changing sentiment against marijuana stocks as well as an oversupply of dried cannabis. * 7 Reasons to Buy Canopy Growth Stock In short, stocks that could do no wrong 18 months ago can now do no right. This bodes poorly for Tilray stock. InvestorPlace's Mark Hake even floated the possibility that TLRY could go bankrupt. Investors cannot write off that possibility as its reserves dwindle.TLRY holds about $180 million in cash. Since it lost $35 million in the last quarter, it can only maintain its current pace for so long. Moreover, Tilray cannot assume further debt will be an option. As of the previous quarterly report, the company held $430 million in long-term debt and $360 million in total equity. Hence, the financials indicate that the company may have to dilute its already beleaguered stock further when it comes time to seek more funding. TLRY Could Recover -- EventuallyDespite a bleak outlook and a lack of profits, investors still have reasons to keep watching Tilray stock. Much like the positive sentiment surrounding marijuana stocks did not last, investors should not assume the negative outlook will remain forever. When attitudes change, Wall Street may again pay attention to Tilray's attributes. Analysts forecast a 313.9% increase in revenue for this year. They also believe revenues will rise an additional 85.5% in fiscal 2020.Moreover, its partnerships and assets could eventually help TLRY. The company has partnered with a subsidiary of Novartis (NYSE:NVS) to distribute and sell branded medical cannabis products. It also entered into a joint venture with Anheuser-Busch InBev (NYSE:BUD) to research THC and CBD-infused beverages. Tilray also owns Manitoba Harvest, the world's largest hemp food manufacturer.This bodes well for continuing revenue growth. However, getting to the point where rising revenues can finally yield profits will probably lead to actions that place more strain on both the balance sheet and TLRY. Until the company can get to a place where it stops diluting Tilray stock, investors have little reason to buy. My Final Thoughts on Tilray StockTilray stock will struggle to move higher without improving its financials and without a more positive outlook from Wall Street on the cannabis sector. The bubble in TLRY continues to pop. The stock still appears pricey despite trading more than 90% below its all-time high. Sentiment has turned against marijuana stocks as losses continue and the industry contends with a glut in dried cannabis.Despite these obstacles, an eventual bullish scenario could develop for Tilray stock. It has built partnerships with established players in other industries. This could bode well for the Nanaimo, British Columbia-based firm as medicinal marijuana and cannabis-infused beverages find a market.However, for now, TLRY stock faces challenges as losses mount and liquid assets dwindle. Options for more funding will probably strain both the balance sheet and Tilray stock itself. For this reason, investors should probably brace for further near-term declines.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Reasons to Buy Canopy Growth Stock * 7 Restaurant Stocks to Leave on Your Plate * 4 Turnaround Plays to Buy Now The post Investors Beware: Tilray Stock Might Not Be Done Dropping appeared first on InvestorPlace.

  • Takeda pares down products and jobs, revives Genzyme building plans
    American City Business Journals

    Takeda pares down products and jobs, revives Genzyme building plans

    Takeda Pharmaceutical Co. Ltd. is shedding dozens of products and an undisclosed number of employees in a $200 million deal. But the Japanese drugmaker is reviving plans to occupy Cambridge’s iconic Genzyme building.

  • MarketWatch

    Incyte reports positive results in late-stage trial of treatment for GVHD

    Incyte Corp. shares rose 1.2% in premarket trade Wednesday, after the biotech said a late-stage trial of a treatment for patients with steroid-refractory acute graft-versus-host disease, or GVHD, met its main goal of improving overall response rate. Wilmington, Delaware-based Incyte said there were no new safety signals in the phase 3 trial evaluating ruxolitinib (Jakafi). GVHD is a condition that can occur after the transfer of stem cells from a donor when the donated cells trigger an immune response and attack the recipient's organs. "GVHD is a challenging and serious disease, and physicians around the world need access to therapies that can improve outcomes for patients," said Peter Langmuir, M.D., group vice president, targeted therapies, at Incyte. The trial, which is sponsored by Novartis as well as Incyte, continues with results expected to be presented in 2020. Incyte shares have gained 23.5% in 2019, while the S&P 500 has gained 19.5%.

  • Sanofi opens new Framingham site amid $1.6B bet on bio-manufacturing
    American City Business Journals

    Sanofi opens new Framingham site amid $1.6B bet on bio-manufacturing

    Sanofi has invested $1.5 billion into expanding over the last five years as it competes with companies like new CEO Paul Hudson’s former company Novartis Corp.

  • Progenics Pharmaceuticals Needs a Treatment for Sickly Corporate Governance
    CorpGov.com

    Progenics Pharmaceuticals Needs a Treatment for Sickly Corporate Governance

    Progenics Pharmaceuticals, Inc. Pushed Through Questionable Merger with Votes from Directors Who Had Resigned Progenics Agreed to Large Termination Fee in Possible Move to Trap Shareholders in Deal Corporate Governance Expert Finds Termination Fee, Lame Duck Director Votes “Troubling” Stock Trading Above Offer Price, Suggesting Shareholders Want A Kiss or Deal Scrapped By John […]

  • New Novartis Drug Tabbed as Blockbuster
    GuruFocus.com

    New Novartis Drug Tabbed as Blockbuster

    Sales of treatment for macular degeneration predicted to top $1 billion by 2026 Continue reading...

  • Is Novartis AG  (NVS) A Good Stock To Buy According To Hedge Funds?
    Insider Monkey

    Is Novartis AG (NVS) A Good Stock To Buy According To Hedge Funds?

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • Here is Hedge Funds’ 30th Most Popular Stock Pick
    Insider Monkey

    Here is Hedge Funds’ 30th Most Popular Stock Pick

    Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Reuters

    CORRECTED-China expands drug bulk-buy programme, puts pressure on pharma firms

    China has expanded a pilot drug bulk-buying programme to the entire country in an attempt to negotiate lower prices from drug manufacturers, heaping fresh pressure on multinational pharmaceutical companies and their domestic rivals. The programme rolled out last year saw 11 Chinese cities, including Beijing and Shanghai, band together behind a tender process to bulk-buy 25 types of drugs. The scheme will be expanded to an additional 25 provinces and regions, who will form a league to look for suppliers for these drugs that will be stocked at public hospitals as well as some military and private medical institutions, according to documents released on Sunday by the drug procurement branch of the Shanghai Healthcare Security Administration.

  • The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation
    Benzinga

    The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Aug. 30.) Inspire Medical Systems Inc (NYSE: INSP ...

  • Novartis takes aim at Roche's star MS drug
    Reuters

    Novartis takes aim at Roche's star MS drug

    Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival's drug Ocrevus. Novartis said ofatumumab, already approved as Arzerra to treat leukaemia, reduced annual relapses better than Sanofi's Aubagio in two head-to-head late-stage studies against relapsing forms of MS (RMS). Detailed study results are due at an MS conference in Sweden next month.

  • Reuters

    UPDATE 2-Novartis takes aim at Roche's star MS drug

    Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival's drug Ocrevus. Novartis said ofatumumab, already approved as Arzerra to treat leukaemia, reduced annual relapses better than Sanofi's Aubagio in two head-to-head late-stage studies against relapsing forms of MS (RMS). Detailed study results are due at an MS conference in Sweden next month.

  • 5 Companies Still Run by Families
    Motley Fool

    5 Companies Still Run by Families

    In a world of large, faceless corporations, it can sometimes be nice to think of family values in business. What are the biggest family-owned businesses around?

  • 5 Biggest New Drug Approvals Potentially on the Way in 2019
    Motley Fool

    5 Biggest New Drug Approvals Potentially on the Way in 2019

    FDA approvals for these drugs could translate to billions of dollars for a few companies.

  • Novartis to answer U.S. Senate demand for data manipulation details
    Reuters

    Novartis to answer U.S. Senate demand for data manipulation details

    Novartis plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval. Novartis, which won approval for Zolgensma in May -- more than a month before it told the Food and Drug Administration of the alleged data fraud -- has terminated several scientists amid an internal investigation.

  • Novartis executive sold shares before drug data manipulation made public
    Reuters

    Novartis executive sold shares before drug data manipulation made public

    An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from tests of its gene therapy Zolgensma had been manipulated. Novartis announced the stock sale by an executive member of the board of directors or a member of the executive committee in a Swiss stock exchange filing dated July 19. The sale was made after the company had informed the FDA about the data manipulation but before the FDA announced it publically on Aug 6.

  • Motley Fool

    A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis

    What Novartis' misstep means to investors, plus how Exact Sciences is trying to lock up the genetic testing market.

  • Reuters

    Novartis replaces top scientists at Avexis after drug data manipulated

    Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million. Avexis' Chief Scientific Officer Brian Kaspar and Senior Vice President of Research and Development Allan Kaspar have not been involved in any operations at Avexis since early May 2019, Novartis said in a statement. Brian Kaspar was a founder and key executive at Avexis and made more than $380 million from the company's 2018 acquisition by Novartis, according to SEC filings.

  • Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data
    Investor's Business Daily

    Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data

    Swiss pharma giant Novartis reportedly fired two scientists at its AveXis unit for manipulating data necessary to gain approval of gene therapy Zolgensma, CNBC reported Wednesday.

  • Reuters

    UPDATE 2-Novartis replaces top scientists at Avexis after drug data manipulated

    Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million. Avexis' Chief Scientific Officer Brian Kaspar and Senior Vice President of Research and Development Allan Kaspar have not been involved in any operations at Avexis since early May 2019, Novartis said in a statement. Brian Kaspar was a founder and key executive at Avexis and made more than $380 million from the company's 2018 acquisition by Novartis, according to SEC filings.